New RA drug KT502 enters first human safety trial
Disease control
Not yet recruiting
This early-stage study tests a new drug called KT502 in 27 adults with moderate to severe rheumatoid arthritis who haven't responded well to other treatments. The goal is to check if the drug is safe, what side effects it may cause, and how the body processes it. Participants wil…
Phase: PHASE1 • Sponsor: Kali Therapeutics, Inc. • Aim: Disease control
Last updated May 18, 2026 12:12 UTC